BOSTON, MA–(Marketwire – March 11, 2010) – A growing volume of global drug development and commercialization activity during the past decade has dramatically increased the workload for regulatory affairs professionals at pharmaceutical and biotech companies, according to a study recently completed by the Tufts Center for the Study of Drug Development.
Further information:
Related posts:
- Intrinsik Announces Acquisition of Carexa Inc.
- The role of funding and policies on innovation in cancer drug development
- Flexible Phase I Study Designs: Expediting Early Clinical Drug Development
- Rondaxe and TD2 form strategic drug development alliance
- QTc prolongation assessment in anticancer drug development: Clinical and methodological issues
Posted in